POSITRON EMISSION TOMOGRAPHY IN DRUG-EVALUATION - INFLUENCE OF 3 DIFFERENT CATECHOL-O-METHYLTRANSFERASE INHIBITORS ON METABOLISM OF [NCA] 6-[F-18]FLUORO-L-DOPA IN RHESUS-MONKEY

被引：19

作者：

GUNTHER, I

PSYLLA, M

REDDY, GN

ANTONINI, A

VONTOBEL, P

REIST, HW

ZOLLINGER, A

NICKLES, RJ

BEER, HF

SCHUBIGER, PA

LEENDERS, KL

机构：

[1] PAUL SCHERRER INST, DEPT PET, CH-5232 VILLIGEN, SWITZERLAND

[2] PAUL SCHERRER INST, DEPT RADIOPHARM, CH-5232 VILLIGEN, SWITZERLAND

[3] UNIV ZURICH HOSP, DEPT ANAESTHESIOL, CH-8091 ZURICH, SWITZERLAND

[4] UNIV WISCONSIN, DEPT MED PHYS, CTR MED SCI 1530, MADISON, WI 53706 USA

来源：

NUCLEAR MEDICINE AND BIOLOGY | 1995年 / 22卷 / 07期

关键词：

D O I：

10.1016/0969-8051(95)00032-S

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We compared the influence of three different catechol-O-methyltransferase (COMT) inhibitors (CGP 28014, OR-611 and Ro 40-7592) on the metabolism of no-carrier-added (NCA) 6-[F-18]fluoro-L-dopa (6-FDOPA) in one Rhesus monkey. All three COMT inhibitors improved 6-FDOPA availability in plasma, increased the specific uptake in the brain and thus improved 6-FDOPA uptake measurements using positron emission tomography (PET). Best results were obtained with Ro 40-7592.

引用

页码：921 / 927

页数：7

共 21 条

[1] REDUCTION OF CIRCULATING 3-O-METHYLDOPA BY INHIBITION OF CATECHOL-O-METHYLTRANSFERASE WITH OR-611 AND OR-462 IN CYNOMOLGUS MONKEYS - IMPLICATIONS FOR THE TREATMENT OF PARKINSONS-DISEASE [J].